Biogen names new chief strategy officer
This article was originally published in Scrip
Executive Summary
Biogen Idec, which develops therapies for neurodegenerative diseases, hemophilia and autoimmune disorders, has named Dr Adam Koppel senior vice-president and chief strategy officer – effective 15 May 2014. Dr Koppel will be responsible for leading corporate strategy and portfolio management, as well as ensuring that disease strategies clearly align with the corporate strategy, Biogen said. He will report to chief executive officer Dr George Scangos, and will become a member of Biogen's management team. Prior to joining the Cambridge, Massachusetts-based firm Dr Koppel was managing director of Brookside Capital, the public equity affiliate of Bain Capital.
You may also be interested in...
Six New Molecules By 2030 – J&J’s Neuroscience Strategy
Can neuroscience be precise? Peter Fang, worldwide VP of neuroscience, explains J&J's approach to precision medicine in Alzheimer’s disease, depression and other neurological conditions.
Accessing Venture Debt From The EIB
Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.
In Vivo's 2024 Rising Leaders At A Glance
Top 30 leaders: see the list of industry influencers highlighted in the fifth edition of In Vivo's Rising Leaders series.